-
1 Comment
Hikma Pharmaceuticals PLC is currently in a long term uptrend where the price is trading 6.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Hikma Pharmaceuticals PLC's total revenue sank by 0.0% to $580M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $150M since the same quarter in the previous year.
Finally, its free cash flow fell by 69.2% to $33M since the same quarter in the previous year.
Based on the above factors, Hikma Pharmaceuticals PLC gets an overall score of 2/5.
ISIN | GB00B0LCW083 |
---|---|
Exchange | F |
CurrencyCode | EUR |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | 5B |
---|---|
Beta | 0.63 |
PE Ratio | 16.64 |
Target Price | None |
Dividend Yield | 3.0% |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for H5P.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025